Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vodobatinib - Sun Pharma Advanced Research Company

Drug Profile

Vodobatinib - Sun Pharma Advanced Research Company

Alternative Names: K-0706; SCO-088; SUN K706; SUN-K0706

Latest Information Update: 25 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antidementias; Antineoplastics; Antiparkinsonians; Benzoic acids; Chlorinated hydrocarbons; Quinolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lewy body disease; Parkinson's disease
  • Phase I/II Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 25 Jul 2022 Vodobatinib is still in phase II trials for Lewy body disease (In the elderly, Treatment-experienced, In adults) in USA (PO) (NCT03996460)
  • 05 Dec 2020 Interim adverse events and efficacy data from a phase I/II trial in Chronic Myeloid Leukemia presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2020)
  • 13 Feb 2020 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top